Patient preference quality of life measures in dermatology

Dermatologic Therapy

Volumn 20, Issue 2, 2007, Pages 102-109

  McCombs, Kathryn ^b   Chen, Suephy C ^a,b,c  

^a Department of Dermatology ^*  (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Quality of life; Standard gamble; Time trade off; Utilities; Willingness to pay

Indexed keywords

ADALIMUMAB; PLACEBO;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DERMATOLOGY; ECONOMIC ASPECT; EVIDENCE BASED MEDICINE; HEALTH CARE; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH STATUS; HEALTH SURVEY; HUMAN; MEASUREMENT; MEDICAL LITERATURE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW;

DERMATOLOGY; HEALTH STATUS INDICATORS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SATISFACTION; PSYCHOMETRICS; QUALITY OF LIFE; VALUE OF LIFE;

EID: 34249307531     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2007.00118.x     Document Type: Review

References (50)

1. Finlay AY. Quality of life measurement in dermatology: a practical guide. Br J Dermatol 1997 : 136 : 305 314.
2. Slevin ML, Plant H, Lynch D, Drinkwater J, Gregory WM. Who should measure quality of life, the doctor or the patient? Br J Cancer 1988 : 57 : 109 112.
3. Ware J, Gandek B. Overview of the SF-36 health survey and the international quality of life assessment (IQOLA) project. J Clin Epidemiol 1998 : 51 : 903 912.
4. Eun HC, Finlay AY. Measurement of atopic dermatitis disability. Ann Dermatol 1990 : 2 : 9 12.
5. Finlay AY, Kelly SE. Psoriasis - an index of disability. Clin Exp Dermatol 1987 : 12 : 8 11.
6. Motley RJ, Finlay AY. How much disability is caused by acne? Clin Exp Dermatol 1989 : 14 : 194 198.
7. Chen SC, Yeung J, Chren MM. Scalpdex: a quality-of-life instrument for scalp dermatitis. Arch Dermatol 2002 : 138 : 803 807.
8. Froberg DG, Kane RL. Methodology for measuring health state preferences. J Clin Epidemiol 1989 : 42 : 345 354.
9. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes, 2nd ed. New York : Oxford University Press, 1997.
10. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986 : 5 : 1 30.
11. Tolley G, Kenkel D, Fabian R (eds). Valuing health for policy: an economic approach. Chicago : University of Chicago Press, 1994.
12. Schiffman RM, Walt JG, Jacobsen G, Doyle JJ, Lebovics G, Sumner W. Utility assessment among patients with dry eye disease. Ophthalmology 2003 : 110 : 1412 1419.
13. King JT, Tsevat J, Roberts MS. Preference-based quality of life in patients with cerebral aneurysms. Stroke 2005 : 36 : 303 309.
14. van Osch SMC, Wakker PP, van den Hout WB, Stiggelbout AM. Correcting biases in standard gamble and time tradeoff utilities. Med Decis Making 2004 : 24 : 511 517.
15. Torrance GW. Social preferences for health states: an empirical evaluation of three measurement techniques. Socio-Econ Plan Sci 1976 : 10 : 129 136.
16. McNeil BJ, Weichselbaum R, Pauker SG. Fallacy of the five-year survival in lung cancer. N Engl J Med 1978 : 299 : 1397 1401.
17. Feeny DH, Torrance GW. Incorporating utility-based quality-of-life assessment measures in clinical trials. Med Care 1989 : 27 : S190 S204.
18. Littenberg B, Partilo S, Licata A, Kattan MW. Paper standard gamble: the reliability of a paper questionnaire to assess utility. Med Decis Making 2003 : 23 : 480 488.
19. Ross PL, Littenberg B, Fearn P, Scardino PT, Karakiewicz PI, Kattan MW. A paper-based measure of standard gamble utility for current health. Int J Technol Assess Health Care 2003 : 19 : 135 147.
20. van Wijck EE, Bosch JL, Hunink MG. Time-tradeoff values and standard-gamble utilities assessed during telephone interviews versus face-to-face interviews. Med Decis Making 1998 : 18 : 400 405.
21. Sumner W, Nease R, Littenberg B. U-titer: a utility assessment tool. Proc Annu Symp Comput Appl Med Care 1991 : 701 705.
22. Lenert LA, Sturley A, Watson ME. iMPACT3: Internet-based development and administration of utility elicitation protocols. Med Decis Making 2002 : 22 : 464 474.
23. Horsman J, Furlong W, Feeny D, Torrance G. The health utilities index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes 2003 : 1 : 54 66.
24. Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 2006 : 4 : 71 82.
25. Weiss SC, Nguyen J, Chon S, Kimball AB. A randomized controlled clinical trial assessing the effect of betamethasone valerate 0.12% foam on the short-term treatment of stasis dermatitis. J Drugs Dermatol 2005 : 4 : 339 345.
26. Bergstrom KG, Arambula K, Kimball AB. Medication formulation affects quality of life: a randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis 2003 : 72 : 407 411.
27. Klassen AF, Newton JN, Mallon E. Measuring quality of life in people referred for specialist care of acne: comparing generic and disease-specific measures. J Am Acad Dermatol 2000 : 43 : 229 233.
28. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989 : 5 : 559 575.
29. Goldstein M, Tsevat J. Applying utility assessment at the "bedside. " In : Chapman GB, Sonnenberg FA, eds. Decision making in health care: theory, psychology, and applications. Cambridge : Cambridge University Press, 2000 : 313.
30. Zug KA, Littenberg B, Baughman RD, et al. Assessing the preferences of patients with psoriasis. Arch Dermatol 1995 : 131 : 561 568.
31. Feeny D, Blanchard CM, Mahon JL, et al. The stability of utility scores: test-retest reliability and the interpretation of utility scores in elective total hip arthroplasty. Qual Life Res 2004 : 13 : 15 22.
32. Hollands H, Lam M, Pater J, et al. Reliability of the time trade-off technique of utility assessment in patients with retinal disease. Can J Ophthalmol 2001 : 36 : 202 209.
33. Badia X, Monserrat S, Roset M, Herdman M. Feasibility, validity and test-retest reliability of scaling methods for health states: the visual analogue scale and the time trade-off. Qual Life Res 1999 : 8 : 303 310.
34. Bakker C, Rutten-van Molken M, Hidding A, van Doorslaer E, Bennet K, van der Linden S. Patient utilities in ankylosing spondylitis and the association with other outcome measures. J Rheumatol 1994 : 21 : 1298 1304.
35. Torrance GW, Boyle MH, Horwood SP. Application of multi-attribute utility theory to measure social preferences for health states. Oper Res 1982 : 30 : 1043 1069.
36. Chen SC, Bayoumi AM, Soon SL, et al. A catalog of dermatology utilities: a measure of the burden of skin diseases. J Invest Dermatol Symp Proc 2004 : 9 : 160 168.
37. Schiffner R, Schiffner-Rohe J, Gerstenhauer M, Hofstadter F, Landthaler M, Stolz W. Willingness to pay and time trade-off: sensitive to changes of quality of life in psoriasis patients? Br J Dermatol 2003 : 148 : 1153 1160.
38. Schiffner R, Brunnberg S, Hohenleutner U, Stolz W, Landthaler M. Willingness to pay and time trade-off: useful utility indicators for the assessment of quality of life and patient satisfaction in patients with port wine stains. Br J Dermatol 2002 : 146 : 440 447.
39. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995 : 132 : 236 244.
40. Finlay AY. Measures of the effect of adult severe atopic eczema on quality of life. J Eur Acad Dermatol Venereol 1996 : 7 : 149 154.
41. Hornberger JC, Redelmeier DA, Petersen J. Variability among methods to assess patients' well-being and consequent effect on a cost-effectiveness analysis. J Clin Epidemiol 1992 : 45 : 505 512.
42. Tsevat J, Solzan JG, Kuntz KM, et al. Health values of patients infected with human immunodeficiency virus. Med Care 1996 : 34 : 44 57.
43. Laupacis A, Bourne R, Rorabeck C, et al. The effect of elective total hip replacement on health-related quality of life. J Bone Joint Surg Am 1993 : 75 : 1619 1626.
44. Gold M, Siegel J, Weinstein MC (eds). Cost-effectiveness in health and medicine. New York : Oxford University Press, 1996.
45. Chen SC, Shaheen A, Garber A. Cost-effectiveness and cost-benefit analysis of using methotrexate vs. goeckerman therapy for psoriasis. Arch Dermatol 1998 : 134 : 1602 1608.
46. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999 : 141 : 1067 1075.
47. Poyner TF, Menday AP, Williams ZV. Patient attitudes to topical antipsoriatic treatment with calcipotriol and dithranol. J Eur Acad Dermatol Venereol 2000 : 14 : 153 158.
48. Schiffner R, Landthaler M, Stolz W. Willingness-to-pay and time-trade-off: useful utilities in patients with psoriasis vulgaris? Dermatol Psychosom 2000 : 1 : 100 103.
49. Pitt M, Garside R, Stein K. A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema. Br J Dermatol 2006 : 154 : 1137 1146.
50. Williamson D, Gonzalez M, Finlay AY. The effect of hair loss on quality of life. J Eur Acad Dermatol Venereol 2001 : 15 : 137 139.